SK Biopharmaceuticals Co Ltd
326030
Company Profile
Business description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.
Contact
221, Pangyoyeok-ro
Bundang-gu
Gyeonggi-do
Seongnam13494
KORT: +82 3180930114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
269
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.60 | 52.90 | 0.59% |
| CAC 40 | 8,474.86 | 137.57 | 1.65% |
| DAX 40 | 25,580.88 | 540.60 | 2.16% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,652.87 | 174.53 | 1.67% |
| HKSE | 23,450.28 | 395.25 | 1.71% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,121.29 | 388.14 | 0.56% |
| NZX 50 Index | 13,616.35 | 34.16 | 0.25% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,822.80 | 53.50 | 0.61% |
| SSE Composite Index | 4,037.14 | 8.23 | 0.20% |